Ladiratuzumab vedotin (SGN-LIV1A) is an ADC (IC 50: 5.6 nM for LIV-1) that targets LIV-1. This compound is composed of a humanized IgG1 monoclonal antibody, linked to MMAE via a protease-cleavable linker. It induces immunogenic cell death (ICD), which triggers an immune response. Ladiratuzumab vedotin is utilized in breast cancer research [1] [2] [3] [4].
Purity:
95.00%
CAS Number:
[1629760-29-7]
Target:
Antibody-Drug Conjugates (ADCs)
* VAT and and shipping costs not included. Errors and price changes excepted
